Beam Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Beam Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Beam Therapeutics: 5 sponsored US clinical trials, 3 recruiting.
Beam Therapeutics sponsors 5 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Sickle Cell Disease, with 2 trials.
Upper-quartile sponsor footprint
Beam Therapeutics sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
A Long-term Follow-up Study in Patients Who Received BEAM-101
NCT07373639
A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa)
NCT06735755
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
NCT06389877
A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
NCT05885464
BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease
NCT05456880
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
What is open in the Beam Therapeutics pipeline
3 recruiting of 5 indexed (60% open).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Sickle Cell Disease (2 trials), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Beam Therapeutics: open-pipeline peers nationwide
Peers matched on 5 registered trials and 60% open enrollment, not the therapeutic-area sidebar.
Beam Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 60% open enrollment (± trial volume)
- Alaska Native Tribal Health Consortium · 60% recruiting · 5 trials
- Anwaar Saeed · 60% recruiting · 5 trials
- Autolus Limited · 60% recruiting · 5 trials
- Bio-Path Holdings · 60% recruiting · 5 trials
Related
What to do with this Beam Therapeutics page
5 registered trials is a research-attention snapshot, not an endorsement of Beam Therapeutics or any single study.
- 3 of Beam Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Sickle Cell Disease is the condition Beam Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Sickle Cell Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Beam Therapeutics pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.